TickerTalks
Browse all tickers →
TickerTalks›$NONOF
NONONOF

Novo Nordisk A/S

$NONOF·$209B·Drug Manufacturers - General·Healthcare
$45.77-1.6%1Y-17.0%
Price updated 42d ago·X counts updated 43d ago
NONONOF
$NONOFNovo Nordisk A/S
$45.77-1.57%0 posts
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $NONOF on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

0X posts · last 7 days
No mention history yet

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $NONOF — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Proven numbersWinding up for a moveAI verdict · as of 2026-08-21

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Novo Nordisk Q2 EPS beat by 23% with Q1 revenue up 24% — GLP-1 leader at 10.7x with tape stuck at 40% of the 52-week range.

Novo Nordisk is a Danish pharmaceutical giant with two divisions — Diabetes and Obesity Care (insulins, GLP-1 agonists including Ozempic and Wegovy, oral antidiabetics) and Biopharmaceuticals (hemophilia, growth disorders). The setup is the GLP-1 category leader in a competitive tug-of-war with Eli Lilly, with tape underperforming despite continued operational strength.

  • Q2 EPS came in at $0.942 versus $0.767 consensus (23% beat) with the pattern of the last four surprises (+23%, +10%, +3%, -8%) net-positive with acceleration — the operating story is stronger than the tape indicates.
  • Q1 revenue was $96.8B DKK, up 24% year-on-year with 62% operating margin — the specific tell that GLP-1 volumes plus pricing are compounding at premium unit economics.
  • Trades at 10.7x trailing earnings, 4x sales, and 8x EV/EBITDA with a 66% return on equity and 32% return on invested capital — the multiples are historically low for a category-leading pharma, reflecting Lilly-competition anxiety.
  • Sits at the 40th percentile of the 52-week range, down 14% year-on-year — the tape has been consolidating despite the Q2 beat, which is the setup for either a catch-up move or continued Lilly-driven relative underperformance.

What breaks the range is Nov 4 Q3 confirming continued GLP-1 volume growth alongside a specific pipeline readout (CagriSema or oral obesity candidate). What extends the coil is a Lilly Zepbound market-share gain data point, a US Medicare-negotiation headline, or a specific EU-pricing pressure event; the operational moat is real, and the current setup offers value with catalysts.

What to watch: Nov 4 Q3 earnings — consensus $0.773 EPS. Watch GLP-1 unit growth (Ozempic + Wegovy), Zepbound competitive dynamics, US Medicare-negotiation updates, and any pipeline readout on CagriSema or oral obesity candidates.

On the calendar: 2026-11-04 — Q3 earnings

float missing

Read the AI verdict on $NONOF

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Danish pharmaceutical company dominating diabetes and obesity treatment with insulin products and GLP-1 drugs Ozempic and Wegovy.

Industry overviewAI analysisGenerated by AI from underlying data

Where Drug Manufacturers - General sits in its cycle right now — and what that implies for $NONOF.

Drug Manufacturers - General · Healthcare

No material change from last week — GLP-1 duopoly (LLY/NVO) drives premium valuations while patent-cliff management defines the rest: ABBV migraine franchise win strengthens post-Humira portfolio.

What this means for $NONOF

Partial — upstream oil & gas exposure ties to commodity price cycle; Novo Nordisk A/S operates as a prominent global pharmaceutic.

Top industry ETF

$IHEiShares U.S. Pharmaceuticals ETF
+14.5%YTD
+36.2%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
10.7How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
32.2%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
45.3%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
2.4%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
4.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
66.4%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
81.8%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.7Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 5, 2026$0.94$0.77+22.8%
Q1 2026May 6, 2026$1.02$0.93+10.3%
Q4 2025Feb 3, 2026$0.95$0.92+2.8%
Q3 2025Nov 5, 2025$0.71$0.77-7.9%
Next earningsWed, Nov 4·consensus EPS $0.77

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$96.8B+24.0%86.0%61.6%$10.93$12.0B
Q4 FY25$79.0B-7.8%81.0%40.2%$6.04$-10.8B
Q3 FY25$75.0B+5.1%76.1%31.6%$4.50$32.5B
Q2 FY25$76.9B+12.9%83.3%43.5%$5.96$24.5B

Forward consensus

5-year forecast · up to 27 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$291.7B$270.5B – $318.8B$21.61$19.22 – $24.7427
FY27$299.4B$270.3B – $338.1B$21.44$19.07 – $24.5426
FY28$319.4B$292.2B – $354.9B$23.25$20.68 – $26.6212
FY29$347.2B$317.7B – $385.8B$26.52$23.59 – $30.3625
FY30$364.0B$333.1B – $404.6B$27.83$24.75 – $31.8615

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.1×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.42%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-1.2%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+1.9%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

β0.355-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.ListedOTCListed on an over-the-counter market (PNK / OTCQB / OTCQX), not a major exchange. Lower disclosure requirements and thinner liquidity.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

No material 8-K / SC 13D / S-3 / 424B5 filings in the last 180 days.

+ 32 other (28 6-Ks · 2 11-Ks · 1 13G · 1 SD) in window

In themes

Explore the broader themes this ticker is being talked about under.

GLP-1 & Weight Loss

More in Drug Manufacturers - General

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$OGN$LLY$NVO$PFE$JNJ$ABBV$MRK$BMY
Voices on X · last 7 days

No standout posts about $NONOF on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport